Home News Hold Off on Approving Anal Cancer Drug, Advisors Tell FDA back to News
minute read
FDA advisors told the agency to wait on more data before approving an investigational immunotherapy for squamous carcinoma of the anal canal (SCAC), largely due to questions over the drug's activity.
Topics: Press Coverage
13001 East 17th Place
Aurora, CO 80045
303.724.5375
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
